The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Abstract
CONTEXT: Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. OBJECTIVES: Our objectives were to confirm weight loss with dapagliflozin and establish through body composition measurements whether weight loss is accounted for by changes in fat or fluid components. DESIGN AND SETTING: This was a 24-wk, international, multicenter, randomized, parallel-group, double-blind, placebo-controlled study with ongoing 78-wk site- and patient-blinded extension period at 40 sites in five countries. PATIENTS: Included were 182 patients with T2DM (mean values: women 63.3 and men 58.6 yr of age; hemoglobin A1c 7.17%, body mass index 31.9 kg/m2, and body weight 91.5 kg) inadequately controlled on metformin. INTERVENTION: Dapagliflozin 10 mg/d or placebo was added to open-label metformin for 24 wk. MAIN OUTCOME MEASURES: Primary endpoint was total body weight (TBW) change from baseline at wk 24. Key secondary endpoints were waist circumference and dual-energy x-ray absorptiometry total-body fat mass (FM) changes from baseline at wk 24, and patient proportion achieving body weight reduction of at least 5% at wk 24. In a subset of patients, magnetic resonance assessment of visceral adipose tissue (VAT) and sc adipose tissue (SAT) volume and hepatic lipid content were also evaluated. RESULTS: At wk 24, placebo-corrected changes with dapagliflozin were as follows: TBW, -2.08 kg [95% confidence interval (CI)=-2.84 to -1.31; P<0.0001]; waist circumference, -1.52 cm (95% CI=-2.74 to -0.31; P=0.0143); FM, -1.48 kg (95% CI=-2.22 to -0.74; P=0.0001); proportion of patients achieving weight reduction of at least 5%, +26.2% (95% CI=15.5 to 36.7; P<0.0001); VAT, -258.4 cm3 (95% CI=-448.1 to -68.6; nominal P=0.0084); SAT, -184.9 cm3 (95% CI=-359.7 to -10.1; nominal P=0.0385). In the dapagliflozin vs. placebo groups, respectively, serious adverse events were reported in 6.6 vs. 1.1%; events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%; and lower urinary tract infections in 6.6 vs. 2.2%. CONCLUSIONS: Dapagliflozin reduces TBW, predominantly by reducing FM, VAT and SAT in T2DM inadequately controlled with metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Grundy, S. M. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.151092 · Cited by 1,616
de Koning, L., Merchant, A. T., Pogue, J., & Anand, S. S. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm026 · Cited by 1,073
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 873
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 725
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629
Flagged first, then by citations
Research works printed but not linked: 1
- Tang, 2003, The financing burden of treatment of diabetes-II and its symptom in urban China., Chin Health Econ, 12, 21
Cited by
Sorted by citations
Items 301–400 of 864
Ueda, T., Kasama, S., Yamamoto, M., Nakano, T., Ueshima, K., Morikawa, Y., Kawata, H., Yoshihisa, A., Nakayama, M., Komatsu, S., et al. (2021) · Circulation Reports · doi:10.1253/circrep.cr-21-0030 · Cited by 38
Napolitano, A., Miller, S. L., Murgatroyd, P. R., Hussey, E. K., Dobbins, R. L., Bullmore, E. T., & Nunez, D. J. (2014) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2013.12.001 · Cited by 36
Kadokura, T., Akiyama, N., Kashiwagi, A., Utsuno, A., Kazuta, K., Yoshida, S., Nagase, I., Smulders, R. A., & Kageyama, S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.07.020 · Cited by 36
Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney
Palmer, B. F., Clegg, D. J., Taylor, S. I., & Weir, M. R. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.008 · Cited by 36
Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
Goto, Y., Otsuka, Y., Ashida, K., Nagayama, A., Hasuzawa, N., Iwata, S., Hara, K., Tsuruta, M., Wada, N., Motomura, S., et al. (2020) · Endocrine Connections · doi:10.1530/ec-20-0082 · Cited by 36
Scheen, A. J. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s193528 · Cited by 35
Ghosh, A., Dutta, K., Bhatt, S. P., Gupta, R., Tyagi, K., Ansari, I. A., Venugopal, V. K., Mahajan, H., Pandey, R. M., Pandey, S., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac138 · Cited by 36
Han, E., Kim, A., Lee, S. J., Kim, J.-Y., Kim, J. H., Lee, W. J., & Lee, B.-W. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0470-9 · Cited by 35
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 70
Lim, L., Tan, A. T. B., Moses, K., Rajadhyaksha, V., & Chan, S. P. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.008 · Cited by 34
Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects
da Silva, J. C., Filho, J. D. S. R., Cavalcanti, C. A. J., Martins, A., & Salles, J. E. N. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00757-y · Cited by 39
Akbari, A., Rafiee, M., Sathyapalan, T., & Sahebkar, A. (2022) · Journal of Diabetes Research · doi:10.1155/2022/7520632 · Cited by 38
Li, C. X., Liu, L. Y., Zhang, C. X., Geng, X. H., Gu, S. M., Wang, Y. Q., Liu, H., Xie, Q., & Liang, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1238399 · Cited by 38
McEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause‐Nilsson, I. A. M., Bhatt, D. L., Leiter, L. A., Johansson, P. A., Mosenzon, O., Cahn, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14308 · Cited by 34
Self-citationChung, S. W., Moon, H.-S., Shin, H., Han, H., Park, S., Cho, H., Park, J., Hur, M. H., Park, M. K., Won, S., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000837 · Cited by 36
Cuypers, J., Mathieu, C., & Benhalima, K. (2013) · Acta Clinica Belgica · doi:10.2143/acb.3349 · Cited by 36
Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?
Lovshin, J. A., & Gilbert, R. E. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0551-3 · Cited by 35
Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
Hinnen, D. A. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815575273 · Cited by 34
Brown, A., Lang, C. C., McCrimmon, R. J., & Struthers, A. D. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0663-6 · Cited by 33
Jiang, Y., Yang, P., Fu, L., Sun, L., Shen, W., & Wu, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.802992 · Cited by 34
Brown, N. J. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.02.003 · Cited by 34
Xu, L., Li, Y., Lang, J., Xia, P., Zhao, X., Wang, L., Yang, Y. P., & Chen, L. (2017) · PeerJ · doi:10.7717/peerj.3405 · Cited by 34
Iordan, L., Gaiţă, L., Timar, R. Z., Avram, V. F., Sturza, A., & Timar, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137057 · Cited by 34
Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus
Liakos, A., Karagiannis, T., Bekiari, E., Boura, P., & Τσάπας, Α. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814560735 · Cited by 36
Hirose, S., Nakajima, S., Iwahashi, Y., Seo, A., Takahashi, T., & Tamori, Y. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.6367 · Cited by 33
Bando, Y., Ogawa, A., Ishikura, K., Kanehara, H., Hisada, A., Notumata, K., Okafuji, K., & Toya, D. (2017) · Diabetology International · doi:10.1007/s13340-016-0302-y · Cited by 33
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
Otagaki, M., Matsumura, K., Kin, H., Fujii, K., Shibutani, H., Matsumoto, H., Takahashi, H., Park, H., Yamamoto, Y., Sugiura, T., et al. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06892-y · Cited by 33
Xiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 35
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 34
Otsuka, H., Yokomizo, H., Nakamura, S., Izumi, Y., Takahashi, M., Obara, S., Nakao, M., Ikeda, Y., Sato, N., Sakamoto, R., et al. (2022) · Biochemical Journal · doi:10.1042/bcj20210700 · Cited by 35
Kashiwagi, A., Yoshida, S., Nakamura, I., Kazuta, K., Ueyama, E., Takahashi, H., Satomi, H., Kosakai, Y., & Kawamuki, K. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12471 · Cited by 32
Kashiwagi, A., Araki, S., & Maegawa, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13329 · Cited by 32
Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
Chung, W., Promrat, K., & Wands, J. R. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i9.533 · Cited by 35
The role of SGLT-2 inhibitors in managing type 2 diabetes
Tsushima, Y., Lansang, M. C., & Makin, V. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20088 · Cited by 33
Arase, Y., Shiraishi, K., Anzai, K., Sato, H., Teramura, E., Tsuruya, K., Hirose, S., Deguchi, R., Toyoda, M., Mine, T., et al. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00785-6 · Cited by 32
Sarcopenia, frailty circle and treatment with sodium–glucose cotransporter 2 inhibitors
Sasaki, T. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12966 · Cited by 31
Systematic Review of Literature Examining Bacterial Urinary Tract Infections in Diabetes
Paudel, S., John, P. P., Poorbaghi, S. L., Randis, T. M., & Kulkarni, R. (2022) · Journal of Diabetes Research · doi:10.1155/2022/3588297 · Cited by 31
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 36
Yanai, H., Katsuyama, H., Hamasaki, H., Adachi, H., Moriyama, S., Yoshikawa, R., & Sako, A. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2385w · Cited by 31
Wolf, P. S., Fellinger, P., Pfleger, L., Beiglböck, H., Krumpolec, P., Barbieri, C., Gastaldelli, A., Harreiter, J., Metz, M., Scherer, T., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1983 · Cited by 31
Sun, L., Deng, C., Gu, Y., He, Y., Yang, L., & Shi, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101876 · Cited by 31
Xie, L., & Wenfang, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120543 · Cited by 35
Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon
Tanrıöver, C., Uçku, D., Akyol, M., Çevik, E., Kanbay, A., Sridhar, V. S., Cherney, D. Z. I., & Kanbay, M. (2022) · Sleep And Breathing · doi:10.1007/s11325-022-02606-1 · Cited by 35
Dapagliflozin: Glucuretic action and beyond
Balakumar, P., Sundram, K., & Dhanaraj, S. A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.03.008 · Cited by 30
Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes)
Fadini, G. P., Zatti, G., Consoli, A., Bonora, E., Sesti, G., Avogaro, A., Consoli, A., Formoso, G., Antenucci, D., Grossi, G., et al. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.08.001 · Cited by 30
Koshizaka, M., Ishikawa, K., Ishibashi, R., Maezawa, Y., Sakamoto, K., Uchida, D., Nakamura, S., Yamaga, M., Yokoh, H., Kobayashi, A., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13340 · Cited by 30
Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
Herat, L. Y., Matthews, J. R., Azzam, O., Schlaich, M. P., & Matthews, V. B. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01170-z · Cited by 31
SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
Klen, J., & Dolžan, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071995 · Cited by 30
Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan
Ohkura, T. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.136 · Cited by 29
Sharma, R., Wilkinson, L., Vražić, H., Popoff, E., Lopes, S. H. K., Kanters, S., & Druyts, E. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1476332 · Cited by 33
Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians
Singh, A. K., Unnikrishnan, A., Zargar, A. H., Kumar, A., Das, A. K., Saboo, B., Sinha, B., Gangopadhyay, K. K., Talwalkar, P., Ghosal, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0562-1 · Cited by 31
Zeng, Y.-H., Liu, S.-C., Lee, C., Sun, F., & Liu, J. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-21486-9 · Cited by 29
Association between Obstructive Sleep Apnea and Heart Failure in Adults—A Systematic Review
Polecka, A., Olszewska, N., Danielski, Ł., & Olszewska, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196139 · Cited by 30
Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus
Mikhail, N. E. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1061501 · Cited by 29
Grandy, S., Langkilde, A. M., Sugg, J. E., Parikh, S. J., & Sjöström, C. D. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12341 · Cited by 29
Self-citationCombination therapy for type 2 diabetes: dapagliflozin plus metformin
Tan, X., & Hu, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1121235 · Cited by 30
Fishman, B., Shlomai, G., Twig, G., Derazne, E., Tenenbaum, A., Fisman, E. Z., Leiba, A., & Grossman, E. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0929-7 · Cited by 30
Freeman, J. S. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2672 · Cited by 27
Dapagliflozin for the treatment of type 2 diabetes
Abdul‐Ghani, M. A., & DeFronzo, R. A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.812632 · Cited by 30
Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression
Yaribeygi, H., Simental‐Mendía, L. E., Barreto, G. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28420 · Cited by 27
SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
Pandey, J., & Tamrakar, A. K. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1612879 · Cited by 28
Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment
Avgoustou, E., Tzivaki, I., Diamantopoulou, G., Zachariadou, T., Avramidou, D., Dalopoulos, V., & Skourtis, A. (2025) · Diagnostics · doi:10.3390/diagnostics15020169 · Cited by 33
Nakajima, H., Okada, S., Mohri, T., Kanda, E., Inaba, N., Hirasawa, Y., Seino, H., Kuroda, H., Hiyoshi, T., Niiya, T., et al. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0313-x · Cited by 28
Sinha, B., Datta, D., & Ghosal, S. (2020) · JGH Open · doi:10.1002/jgh3.12473 · Cited by 26
Hwang, J. G., Lee, S., Huh, W., Han, J., Oh, J., Jang, I., & Yu, K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15348 · Cited by 28
Liu, X., Chen, Y., Liu, T., Cai, L., Yang, X., & Mou, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1115321 · Cited by 29
Kurinami, N., Sugiyama, S., Nishimura, H., Morita, A., Yoshida, A., Hieshima, K., MIYAMOTO, F., Kajiwara, K., Jinnouchi, K., Jinnouchi, T., et al. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0580-6 · Cited by 29
ナトリウム・グルコース共輸送体2（SGLT2）阻害薬カナグリフロジンは非糖尿病マウスの遅筋および速筋に異なる影響を及ぼす
Otsuka, H. (2023) · Kyushu University Institutional Repository (QIR) (Kyushu University) · Cited by 27
Dapagliflozin: a review on efficacy, clinical effectiveness and safety
Paisley, A. N., Yadav, R., Younis, N., Rao‐Balakrishna, P., & Soran, H. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.740009 · Cited by 27
Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
Budoff, M. J., & Wilding, J. P. H. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12948 · Cited by 27
Self-citationTakada, S., Sabe, H., & Kinugawa, S. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00100.2021 · Cited by 29
Horibe, K., Morino, K., Miyazawa, I., Tanaka‐Mizuno, S., Kondo, K., Sato, D., Ohashi, N., Ida, S., Yanagimachi, T., Yoshimura, M., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109781 · Cited by 26
Kalra, S., Ghosh, S. K., Aamir, A., Ahmed, M. T., Amin, M. F., Bajaj, S., Baruah, M., Bulugahapitiya, U., Das, A., Giri, M., et al. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.196029 · Cited by 26
Yoshida, A., Matsubayashi, Y., Nojima, T., Suganami, H., Abe, T., Ishizawa, M., Fujihara, K., Tanaka, S., Kaku, K., & Sone, H. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02254 · Cited by 30
Figueiredo, I. R., Rose, S. C. P., Freire, N. B., Patrocínio, M. S., Pierdoná, N., & Bittencourt, R. J. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.2.246 · Cited by 26
SGLT2 Inhibitors to Control Glycemia in Type 2 Diabetes Mellitus: A New Approach to an Old Problem
Jabbour, S. A. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.01.2731 · Cited by 26
Terauchi, Y., Tamura, M., Senda, M., Gunji, R., & Kaku, K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13213 · Cited by 25
D’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 25
Cuatrecasas, G., de Cabo, F., Coves, M. J., Patrascioiu, I., Aguilar, G., Cuatrecasas, G., March, S., Calbo, M., Rossell, O., Balfegó, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61590-6 · Cited by 29
Bando, Y., Tohyama, H., Aoki, K., Kanehara, H., Hisada, A., Okafuji, K., & Toya, D. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.06.001 · Cited by 23
Mende, C. W. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1271779 · Cited by 25
Dapagliflozin‐Induced Acute Pancreatitis: A Case Report and Review of Literature
Sujanani, S., Elfishawi, M., Zarghamravanbaksh, P., Cuevas, F., & Reich, D. (2020) · Case Reports in Endocrinology · doi:10.1155/2020/6724504 · Cited by 25
The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes
Katz, P. M., & Leiter, L. A. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.001 · Cited by 24
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Brown, E. E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.013 · Cited by 25
Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators
García‐Vega, D., González‐Juanatey, J. R., & Eirás, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147886 · Cited by 26
New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling
Chen, Y., & Peng, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110072 · Cited by 28
Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
Solini, A. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0856-y · Cited by 25
Kawata, T., Iizuka, T., Iemitsu, K., Takihata, M., Takai, M., Nakajima, S., Minami, N., Umezawa, S., Kanamori, A., Takeda, H., et al. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3038w · Cited by 24
Heerspink, H. J. L., Sjöström, C. D., Inzucchi, S. E., Hallow, K. M., Cain, V. A., Rossing, P. R., Stefánsson, B. V., & Sartipy, P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13579 · Cited by 24
Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G. D., Monda, M., & Marra, M. L. (2025) · Healthcare · doi:10.3390/healthcare13121437 · Cited by 32
Orme, M. E., Fenici, P., Duprat-Lomon, I., Wygant, G. D., Townsend, R., & Roudaut, M. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-73 · Cited by 23
de Wit, H. M., Groen, M. T., Rovers, M. M., & Tack, C. J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12925 · Cited by 24
Giorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14055 · Cited by 23
Moinul, M., Amin, S. A., Kumar, P., Patil, U. K., Gajbhiye, A., Jha, T., & Gayen, S. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.108106 · Cited by 23
Song, T., Chen, S., Zhao, H., Wang, F., Song, H., Tian, D., Yang, Q., & Qi, L. (2021) · Hepatology Research · doi:10.1111/hepr.13645 · Cited by 23
Shao, S., Chang, K., Chien, R., Lin, S., Hung, M., Chan, Y., Yang, Y. K., & Lai, E. C. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13875 · Cited by 22
Post, A., Groothof, D., Eisenga, M. F., & Bakker, S. J. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051603 · Cited by 22
Mellander, A., Billger, M. A., JOHNSSON, E. K., Träff, A. K., Yoshida, S., & Johnsson, K. M. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0438-3 · Cited by 24
Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
Zeng, Q., Zhou, Q., Liu, W., Wang, Y., Xu, X., & Xu, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.636152 · Cited by 23
The Role of the Kidney and Sodium-Glucose Cotransporter-2 Inhibition in Diabetes Management
Valentine, V. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.4.151 · Cited by 26
Metadata
- Authors
- Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S.
- Affiliations
- Karolinska University Hospital (SE)
- Uppsala University Hospital (SE)
- Aintree University Hospital (GB)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- Corresponding author
- Bolinder, Jan
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-03-01
- Volume
- 97
- Issue
- 3
- Pages
- 1020-1031
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2167245776
- Cited by
- 867
- References
- 36
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 51 · 2023: 76 · 2022: 76 · 2021: 70 · 2020: 85 · 2019: 54 · 2018: 53 · 2017: 72 · 2016: 62 · 2015: 53 · 2014: 79 · 2013: 42 · 2012: 17
- FWCI
- 48.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, weight loss, body composition, fat mass, visceral adipose tissue, subcutaneous adipose tissue, hepatic fat content, metformin, inadequate glycemic control, waist circumference, fluid balance, urinary glucose excretion, glycemic control
- MeSH terms
- Adipose Tissue, Adult, Aged, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucosides, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Body Mass Index, Treatment Outcome, Body Fat Distribution, Sodium-Glucose Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
